Briana Contreras speaks with Dan Knecht, Vice President of Clinical Product at CVS Health about telehealth, patient access, CVS minute clinics and Path to Better Health.
Briana Contreras, associate editor of Managed Healthcare Executive speaks with Dan Knecht, Vice President of Clinical Product at CVS Health in this week's episode. During the discussion, they spoke about telehealth, patient access to it, CVS minute clinics and most importantly, CVS Health’s recent study, Path to Better Health. This annual study includes responses from consumers and providers who were asked for their thoughts on the state of healthcare.
Dan Knecht, Vice President of Clinical Product at CVS Health
To listen to more episodes featured on Tuning Into The C-Suite, visit us on Spotify, Apple Podcasts and iHeartRadio.
In the Scope of Virtual Health and the Future of “Website” Manner, Per Ateev Mehrotra
August 10th 2023Briana Contreras, an editor of Managed Healthcare Executive, had the pleasure of catching up with MHE Editorial Advisory Board Member, Ateev Mehrotra, MD, MPH, who is a professor of healthcare policy at Harvard Medical School and an Associate Professor of Medicine and Hospitalist at Beth Israel Deaconess Medical Center.
Listen
Extending the Capabilities of the EHR Through Automation
August 2nd 2023Welcome back to another episode of "Tuning In to the C-Suite," where Briana Contreras, an editor of Managed Healthcare Executive, had the pleasure of chatting with Cindy Gaines, chief clinical transformation officer at Lumeon.
Listen
Information Blocking Will Cost Hospitals, Other Providers Under Proposed ONC Rules
March 5th 2024Hospitals and healthcare software developers are adjusting to a world in which blocking healthcare data will come with potentially stiff penalties under rules proposed by the Office of the National Coordinator for Health Information Technology (ONC).
Read More
Florida Gets the OK. But Will Drug Importation from Canada Actually Happen?
March 5th 2024Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.
Read More